Targeted Metabolic Reprogramming to Improve the Efficacy of Oncolytic Virus Therapy

Mol Ther. 2020 Jun 3;28(6):1417-1421. doi: 10.1016/j.ymthe.2020.03.014. Epub 2020 Mar 20.

Abstract

Oncolytic viruses (OVs) represent a promising new class of cancer therapeutics and cause antitumor effects by two major mechanisms: (1) directly killing cancer cells in a process known as oncolysis, or (2) initiating a powerful antitumor immune response. Interestingly, energy metabolism, within either cancer cells or immune cells, plays a pivotal role in defining the outcome of OV-mediated antitumor effects. Following therapeutic administration, OVs must hijack host cell metabolic pathways to acquire building blocks such as nucleotides, lipids, and amino acids for the process of replication that is necessary for oncolysis. Additionally, OV-stimulated antitumor immune responses are highly dependent on the metabolic state within the tumor microenvironment. Thus, metabolic reprogramming strategies bear the potential to enhance the efficacy of both OV-mediated oncolysis and antitumor immune responses.

Keywords: TCA cycle; cancer metabolism; glycolysis; immunometabolism; metabolic reprogramming; oncolytic virus; oxidative phosphorylation; pyruvate metabolism.

Publication types

  • Review

MeSH terms

  • Animals
  • Cellular Reprogramming / genetics*
  • Energy Metabolism / genetics*
  • Genetic Therapy* / adverse effects
  • Genetic Therapy* / methods
  • Genetic Vectors / administration & dosage
  • Genetic Vectors / genetics*
  • Humans
  • Immunomodulation
  • Metabolic Networks and Pathways / genetics
  • Neoplasms / etiology
  • Neoplasms / metabolism
  • Neoplasms / therapy
  • Oncolytic Virotherapy* / adverse effects
  • Oncolytic Virotherapy* / methods
  • Oncolytic Viruses / genetics*
  • Oxidative Phosphorylation
  • Treatment Outcome